AR122351A1 - Derivados de metilquinazolinona como inhibidores de braf - Google Patents

Derivados de metilquinazolinona como inhibidores de braf

Info

Publication number
AR122351A1
AR122351A1 ARP200103417A ARP200103417A AR122351A1 AR 122351 A1 AR122351 A1 AR 122351A1 AR P200103417 A ARP200103417 A AR P200103417A AR P200103417 A ARP200103417 A AR P200103417A AR 122351 A1 AR122351 A1 AR 122351A1
Authority
AR
Argentina
Prior art keywords
methylquinazolinone
derivatives
braf inhibitors
compounds
braf
Prior art date
Application number
ARP200103417A
Other languages
English (en)
Spanish (es)
Inventor
Cosimo Dolente
David Hewings
Daniel Hunziker
Daniela Krummenacher
Piergiorgio Pettazzoni
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR122351A1 publication Critical patent/AR122351A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP200103417A 2019-12-10 2020-12-09 Derivados de metilquinazolinona como inhibidores de braf AR122351A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19214941 2019-12-10

Publications (1)

Publication Number Publication Date
AR122351A1 true AR122351A1 (es) 2022-09-07

Family

ID=68848113

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103417A AR122351A1 (es) 2019-12-10 2020-12-09 Derivados de metilquinazolinona como inhibidores de braf

Country Status (18)

Country Link
US (1) US20220298119A1 (ko)
EP (1) EP4073065A1 (ko)
JP (2) JP7108146B2 (ko)
KR (1) KR20220110554A (ko)
CN (1) CN114787156A (ko)
AR (1) AR122351A1 (ko)
AU (1) AU2020403443B2 (ko)
BR (1) BR112022011123A2 (ko)
CA (1) CA3162883A1 (ko)
CL (1) CL2022001529A1 (ko)
CO (1) CO2022008968A2 (ko)
CR (1) CR20220251A (ko)
IL (1) IL292161A (ko)
MX (1) MX2022006783A (ko)
PE (1) PE20221778A1 (ko)
TW (1) TW202136245A (ko)
WO (1) WO2021116055A1 (ko)
ZA (1) ZA202204675B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL307964A (en) * 2021-06-09 2023-12-01 Chugai Pharmaceutical Co Ltd Combined treatment for cancer
BR112023025738A2 (pt) * 2021-06-09 2024-02-27 Hoffmann La Roche Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção
EP4352051A1 (en) * 2021-06-09 2024-04-17 F. Hoffmann-La Roche AG New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
WO2023008462A1 (ja) 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び／又は予防のための医薬品
WO2023078881A1 (en) 2021-11-04 2023-05-11 F. Hoffmann-La Roche Ag Novel use of quinazolinone compound for the treatment of cancer
WO2024017294A1 (zh) * 2022-07-19 2024-01-25 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
CN107801378A (zh) * 2015-05-22 2018-03-13 普莱希科公司 用于治疗braf‑v600相关的疾病的plx‑8394或plx‑7904
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物

Also Published As

Publication number Publication date
JP2022531609A (ja) 2022-07-07
CL2022001529A1 (es) 2023-02-10
CO2022008968A2 (es) 2022-07-19
EP4073065A1 (en) 2022-10-19
BR112022011123A2 (pt) 2022-08-23
ZA202204675B (en) 2022-12-21
TW202136245A (zh) 2021-10-01
MX2022006783A (es) 2022-07-11
AU2020403443A1 (en) 2022-05-12
CR20220251A (es) 2022-07-11
US20220298119A1 (en) 2022-09-22
WO2021116055A1 (en) 2021-06-17
JP7108146B2 (ja) 2022-07-27
AU2020403443B2 (en) 2023-02-23
CA3162883A1 (en) 2021-06-17
IL292161A (en) 2022-06-01
PE20221778A1 (es) 2022-11-16
JP2022124458A (ja) 2022-08-25
CN114787156A (zh) 2022-07-22
KR20220110554A (ko) 2022-08-08

Similar Documents

Publication Publication Date Title
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
CO2018008916A2 (es) Compuestos de benzopirazol y análogos de estos
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CL2019001077A1 (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer.
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
AR063096A1 (es) Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112016028818A2 (pt) composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo.
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
ECSP22018571A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
BR112021022536A2 (pt) Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
PH12019500036A1 (en) Heterocyclic compound used as fgfr inhibitor
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2021007247A (es) Derivados de rapamicina.
MX2021012105A (es) Compuestos de pirrol.
CR20220199A (es) Inhibidores del factor d del complemento para administración oral
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia